Posts tagged Jason Mccarthy


Maxim Chimes in on Kite Pharma Inc (KITE) Following Healthcare Conference in China

Maxim analyst Jason McCarthy is out today with a research note on shares of Kite Pharma Inc …

Keryx Biopharmaceuticals (KERX): Focusing On Auryxia Growth

Maxim analyst Jason McCarthy is out today with a new research note on shares of Keryx Biopharmaceuticals …

Maxim Weighs In on Inovio Pharmaceuticals Inc (INO) Following Positive Clinical Data for MERS and ZIKA Vaccines

Maxim analyst Jason McCarthy reiterated a Hold rating on shares of Inovio Pharmaceuticals Inc (NASDAQ:INO), …

Maxim Weighs in on OncoSec Medical Inc (ONCS) Ahead of Immune Data Presentation

OncoSec Medical Inc (NASDAQ:ONCS) shares are rising almost 8% ahead of the biotech firm’s immune …

Keeping The Faith: Maxim Maintains Buy on Juno Therapeutics Inc (JUNO) Despite ROCKET Trial Concerns

Maxim analyst Jason McCarthy provides insight on Juno Therapeutics Inc (NASDAQ:JUNO) amid the hold placed …

Maxim Lifts Price Target for Galena Biopharma Inc (GALE) Ahead of Two Forthcoming Presentations

Galena Biopharma Inc (NASDAQ:GALE) has announced it will have two post presentations at next week’s …

Maxim Slashes Price Target for Juno Therapeutics Inc (JUNO), But Remains Bullish

In a research report published Wednesday, Maxim analyst Jason McCarthy reiterated a Buy rating on …

Maxim Bullish on Galena Biopharma Inc (GALE); Excited to See GALE-401 Going to Pivotal Study in 2017

Yesterday, Galena Biopharma Inc (NASDAQ:GALE) released third-quarter earnings and offered a clinical progress update on …

Maxim Heads to Sidelines on Opexa Therapeutics Inc (OPXA); Here’s Why

As the biotech community debates Opexa Therapeutics Inc’s (NASDAQ:OPXA) clinical trial setback in Secondary Progressive Multiple Sclerosis …

Show More